ResearchOutcomes of patients with de novo oligometastatic breast cancer treated with curative intent at a single institution
ResearchBridging the Gap: Advancing First-Line Therapy for Patients With Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
ResearchImmunoprofiling at an Institutional Scale Reveals That High Numbers of Intratumoral CD8+ and PD-1+ Cells Predict Superior Patient Survival Across Major Cancer Types Independent of Major Risk Factors
ResearchIntegration of Gene Expression and Digital Histology to Predict Treatment-Specific Responses in Breast Cancer
ResearchDetection of heterogeneous resistance mechanisms to tyrosine kinase inhibitors from cell-free DNA
ResearchAPOE+ Tumor-Associated Macrophages and CD4-DOCK4 T Cells Reveal Distinct Microenvironmental Features in HER2-Low and HER2-0 Hormone Receptor-Positive Breast Cancer
ResearchNeoadjuvant therapy with eribulin, doxorubicin and cyclophosphamide for patients with HER2-negative inflammatory breast cancer: a phase II study
ResearchUnveiling the molecular and immunological drivers of antibody-drug conjugates in cancer treatment
ResearchEfficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pembrolizumab in hormone receptor-positive breast cancer: A randomized pilot trial
ResearchCellular reprogramming during anti-PD-1 and chemotherapy treatment in early-stage primary hormone receptor-positive breast cancer
ResearchA phase Ib study of sapacitabine and olaparib in patients with BRCA1/2-mutated metastatic breast cancer
ResearchAssessing the accuracy of inflammatory breast cancer self-reported diagnoses through the metastatic breast cancer project from the count me in initiative database